| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 524 | 2018 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 353 | 2021 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 345 | 2018 |
| Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study A Younes, J Brody, C Carpio, A Lopez-Guillermo, D Ben-Yehuda, ... The Lancet Haematology 6 (2), e67-e78, 2019 | 187 | 2019 |
| Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II … WG Wierda, JN Allan, T Siddiqi, TJ Kipps, S Opat, A Tedeschi, XC Badoux, ... Journal of Clinical Oncology 39 (34), 3853, 2021 | 153 | 2021 |
| Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications BJ Kuss, HJ Eyre, SA Lane, JK Nancarrow, SA Whitmore, DF Callen, ... The Lancet 343 (8912), 1531-1534, 1994 | 139 | 1994 |
| Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort CS Tam, JN Allan, T Siddiqi, TJ Kipps, R Jacobs, S Opat, PM Barr, ... Blood, The Journal of the American Society of Hematology 139 (22), 3278-3289, 2022 | 117 | 2022 |
| Resistance to proteasome inhibitors and other targeted therapies in myeloma CT Wallington‐Beddoe, M Sobieraj‐Teague, BJ Kuss, SM Pitson British Journal of Haematology 182 (1), 11-28, 2018 | 93 | 2018 |
| BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax VS Lin, TE Lew, SM Handunnetti, P Blombery, T Nguyen, DA Westerman, ... Blood, The Journal of the American Society of Hematology 135 (25), 2266-2270, 2020 | 87 | 2020 |
| Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma WY Tong, M Alnakhli, R Bhardwaj, S Apostolou, S Sinha, C Fraser, ... Journal of nanobiotechnology 16, 1-17, 2018 | 80 | 2018 |
| Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase … CS Tam, T Siddiqi, JN Allan, TJ Kipps, IW Flinn, BJ Kuss, S Opat, PM Barr, ... Blood 134, 35, 2019 | 56 | 2019 |
| Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS … WG Wierda, CS Tam, JN Allan, T Siddiqi, TJ Kipps, S Opat, A Tedeschi, ... Blood 136, 16-17, 2020 | 55 | 2020 |
| In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: A potential role in neuroblastoma therapy BJ Kuss, M Corbo, WM Lau, DA Fennell, NM Dean, FE Cotter International journal of cancer 98 (1), 128-133, 2002 | 53 | 2002 |
| Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition TE Lew, VS Lin, ER Cliff, P Blombery, ER Thompson, SM Handunnetti, ... Blood Advances 5 (20), 4054-4058, 2021 | 48 | 2021 |
| Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study MS Davids, BJ Kuss, P Hillmen, M Montillo, C Moreno, J Essell, ... Clinical Cancer Research 26 (9), 2096-2103, 2020 | 40 | 2020 |
| Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). WG Wierda, T Siddiqi, I Flinn, XC Badoux, TJ Kipps, JN Allan, A Tedeschi, ... Journal of Clinical Oncology 36 (15_suppl), 7502-7502, 2018 | 40 | 2018 |
| Small interfering RNA delivery by polyethylenimine-functionalised porous silicon nanoparticles MH Kafshgari, M Alnakhli, B Delalat, S Apostolou, FJ Harding, E Mäkilä, ... Biomaterials science 3 (12), 1555-1565, 2015 | 38 | 2015 |
| Cancer-targeting siRNA delivery from porous silicon nanoparticles Y Wan, S Apostolou, R Dronov, B Kuss, NH Voelcker Nanomedicine 9 (15), 2309-2321, 2014 | 38 | 2014 |
| Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis … P Ghia, JN Allan, T Siddiqi, TJ Kipps, R Jacobs, S Opat, PM Barr, ... Journal of Clinical Oncology 39 (15_suppl), 7501-7501, 2021 | 37 | 2021 |
| Antisense-time to shoot the messenger B Kuss, F Cotter Annals of oncology 10 (5), 495-504, 1999 | 34 | 1999 |
Constantine TamVerified email at tpg.com.au
